Assessment of factors influencing blood pressure control in a managed care population

Pharmacotherapy

Volumn 23, Issue 8, 2003, Pages 1060-1070

  Romain, Tanya M ^a,b   Patel, Rosalie P ^c   Heaberlin, Andrea M ^a   Zarowitz, Barbara J ^c  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GANGLION BLOCKING AGENT; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DIABETES MELLITUS; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH CARE PLANNING; HEALTH MAINTENANCE ORGANIZATION; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; PRIMARY MEDICAL CARE;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; COHORT STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS; DISEASE MANAGEMENT; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYPERTENSION; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 0041347958     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.8.1060.32879     Document Type: Article

References (48)

1. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-VI). Arch Intern Med 1997;157:2413-45.
2. National Institutes of Health, National Heart, Lung and Blood Institute. Morbidity and mortality: 2002 chart book on cardiovascular, lung and blood diseases. Bethesda, MD: National Institutes of Health, National Heart, Lung and Blood Institute, 2002.
3. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population: results from the third national health and nutrition examination survey, 1988-1991. Hypertension 1995;25:305-13.
4. Chobanian AV. Control of hypertension - an important national priority [editorial]. N Engl J Med 2001;345(7):534-5.
5. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998;20:671-81.
6. Hill MN, Bone LR, Kim MT, Miller DJ, Dennison CR, Levine DM. Barriers to hypertension care and control in young urban black men. Am J Hypertens 1999;12:951-8.
7. Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD. Persistence with treatment for hypertension in actual practice. Can Med Assoc J 1999;160(1):31-7.
8. Alexander M, Tekawa I, Hunkeler E, et al. Evaluating hypertension control in a managed care setting. Arch Intern Med 1999;159:2673-7.
9. Hyman D, Pavlik VN. Self-reported hypertension treatment practices among primary care physicians: blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicine. Arch Intern Med 2000;160:2281-6.
10. Hyman D, Pavlik VN, Vallbona C. Physician role in the lack of awareness and control of hypertension. Clin Hypertens 2000;2:324-30.
11. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 2001;345(7):479-86.
12. Oliveria SA, Lapuerta P, McCarthy BD, L'Italien GJ, Berlowitz DR, Asch SM. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med 2002;162:413-20.
13. National Committee for Quality Assurance. Controlling high blood pressure. The state of managed care quality. Washington, DC: NCQA Publications, 2002.
14. Lee JY, Kusek JW, Greene PG, et al. Assessing medication adherence by pill count and electronic monitoring in the African American study of kidney disease and hypertension pilot study. Am J Hypertens 1996;9:719-25.
15. Paramore LC, Halpern MT, Lapuerto P, et al. Impact of poorly controlled hypertension on healthcare resource utilization and cost. Am J Managed Care 2001;7:389-98.
16. Venturini F, Nichol MB, Sung J, Bailey KL, Cody C, McCombs JS. Compliance with sulfonylureas in a health maintenance organization: a pharmacy record-based study. Ann Pharmacother 1999;33:281-8.
17. Christensen DB, Williams B, Goldberg HI, Martin DP, Engelberg R, LoGerfo JP. Assessing compliance to antihypertensive medications using computer-based pharmacy records. Managed Care 1997;35(11):1164-70.
18. Elliott WJ, Toth SJ, Stemer A, Cadwalader JH. Detection, treatment and control of adult hypertension in northwest Indiana. Am J Hypertens 1999;12:830-4.
19. DiTuza L, Luzier AB, Jorosz DE, Synder BD, Izzo JL. Treatment of hypertension in a managed care population. Am J Managed Care 2001;7:520-4.
20. Faulkner LA, Schauffleur HH. The effect of health insurance coverage in the appropriate use of recommended clinical services. Am J Prevent Med 1997;13(6):453-8.
21. Balkrishnan R. Predictors of medication adherence in the elderly. Clin Ther 1998;20(4):764-71.
22. Paris W, Dunham S, Sebastian A, Jacobs C, Nour B. Medication adherence and its relation to financial restriction. J Transplant Coord 1999;9(3):149-52.
23. Bertakis KD, Callahan EJ, Helms LJ, Azari R, Robbins JA. The effect of patient health status on physician practice style. Fam Med 1993;25(8):530-5.
24. Hall JA, Roter DL, Milburn MA, Daltroy LH. Patients' health as a predictor of physician and patient behavior in medical visits. A synthesis of four studies. Med Care 1996;34(12):1205-18.
25. Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. Can Med Assoc J 1999;160(1):41-6.
26. Messerli FH, Ventura HO. Cardiovascular pathophysiology of essential hypertension: a clue to therapy. Drugs 1985;30(suppl 1):25-34.
27. Black HR. Management of patients with refractory hypertension. In: Izzo JL, Black HR, eds. Hypertension primer, 2nd ed. The essentials of high blood pressure. Dallas, TX: American Heart Association, 1999:354-7.
28. Alt RL. Where the boys are not: a brief overview of male preventive health. World Med J 2002;101(4):22-7.
29. Nathanson CA. Sex roles as variables in preventive health behavior. J Community Health 1977;3(2):142-55.
30. Eisler RM, Skidmore JR, Ward CH. Masculine gender role-stress: predictor of anger, anxiety and health-risk behaviors. J Pers Assess 1998;52(1):133-41.
31. Costa FV. Compliance with antihypertensive treatment. Clin Exp Hypertens 1996;18(3-4):463-72.
32. Shea S, Misra D, Ehrlich MH, Francis CK. Correlates of nonadherence to hypertension treatment in an inner city minority population. Am J Public Health 1992;82:1607-12.
33. Marentette MA, Gerth WC, Billings DK, Zarnke KB. Antihypertensive persistence and drug class. Can J Cardiol 2002;18(6):649-56.
34. Di Bari M, Salti F, Nardi M, et al. Undertreatment of hypertension in community-dwelling older adults: a drug utilization study in Dicomano, Italy. J Hypertens 1999; 17(11):1633-40.
35. Carter BL. Management of essential hypertension. In: Mueller BA, Bertch KE, Dunsworth TS, et al, eds. Pharmacotherapy self-assessment program, 4th ed. Book 1. Cardiovascular I and cardiovascular II. Kansas City, MO: American College of Clinical Pharmacy, 2001.
36. Hansson L, Zanchetti A, Carruthers G, et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the HOT randomized trial. Lancet 1998;351:1755-62.
37. United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 28. BMJ 1998;317:703-13.
38. Oparil S, Calhoun DA. Managing the patient with hard-to-control hypertension. Am Fam Physician 1998;7:1007-14.
39. Godley P, Nguyen A, Yokoyama K, Rohack J, Woodward B, Chiang T. Improving hypertension care in a large group-model MCO. Am J Health-Syst Pharm 2003;60(6):554-64.
40. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 2002;4(6):393-404.
41. Stephenson J. Non-compliance may cause half of antihypertensive drug failures. JAMA 1999;282(4):331-14.
42. Waeber B, Burnier M, Brunner HR. Compliance with antihypertensive therapy. Clin Exp Hypertens 1999;21(5):973-85.
43. Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998;339:1951-63.
44. Kyngas H, Lahdenpera T. Compliance of patients with hypertension and associated factors. J Adv Nurs 1999;29(4):832-9.
45. Feldman R, Bacher H, Campbell N, Drover A, Chockalingam A. Adherence to pharmacologic management of hypertension. Can J Public Health 1998;89:116-18.
46. Klein LE. Compliance and blood pressure control. Hypertension 1998;11(suppl 11):11-61.
47. Shaw E, Anderson JG, Maloney M, Jay SJ, Fagan D. Factors associated with non-compliance of patients taking antihypertensive medications. Hosp Pharm 1995;30(3):201-7.
48. Hamilton RA, Briceland LL. Use of prescription-refill records to assess patient compliance. Am J Hosp Pharm 1992;49: 1691-6.